Journal Information
Vol. 84. Issue 4.
Pages 511-512 (October - December 2019)
Vol. 84. Issue 4.
Pages 511-512 (October - December 2019)
Clinical image in Gastroenterology
DOI: 10.1016/j.rgmxen.2019.03.003
Open Access
Protein-losing enteropathy: An uncommon initial manifestation of systemic lupus erythematosus
Enteropatía perdedora de proteínas: una manifestación inicial poco habitual de lupus eritematoso sistémico
Visits
...
J.A. González-Regueiroa,
Corresponding author
regueiro_jose@hotmail.com

Corresponding author. Vasco de Quiroga 15, Belisario Domínguez SXVI, Mexico City, Mexico. 54-87-09-00 o 55-41-91-54-25
, O.C. Rico-Rodríguezb, M.A. Valdovinos-Díaza
a Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», Mexico City, Mexico
b Departamento de Imagenología, Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», Mexico City, Mexico
Article information
Full Text
Download PDF
Statistics
Figures (3)
Show moreShow less
Full Text

A 68-year-old woman presented with abdominal pain associated with anasarca and hypoalbuminemia of 2.5g/dl, with no significant proteinuria. Computed tomography revealed pleural effusion, pericardial effusion, ascites, and soft tissue edema (fig. 1). Malnutrition, nephropathy, and liver failure were ruled out. 99mTc-labeled human albumin scintigraphy and SPECT/CT were carried out, identifying characteristic findings of protein-losing enteropathy (PLE) (figs. 2 and 3). Immunologic study results were: low complement (C3, 49 IU/ml; C4, 7 IU/ml), antinuclear antibodies (1:5120) with a nucleolar pattern, and anti-double-stranded DNA antibodies (65.9 IU/ml). Systemic lupus erythematosus (SLE) was diagnosed. The patient was treated with diuretics and prednisone at a dose of 1mg/kg/day, resulting in significant symptom improvement.

Figure 1.

Coronal view of the abdominal and pelvic tomography scan showing pleural effusion (arrow), pericardial effusion (hollow arrow), ascites (asterisks [*]), and soft tissue edema.

(0.09MB).
Figure 2.

99mTc-labeled human albumin scintigraphy 4h after the intravenous injection, showing the usual biodistribution of the radiopharmaceutical in the liver and its elimination through the urinary tract, with no abnormal concentration of the radiotracer.

(0.03MB).
Figure 3.

Coronal view of the SPECT/CT with 99mTc-labeled human albumin scintigraphy showing diffuse concentration of the radiotracer in the lumen of the jejunum and ileum (hollow arrows), with intestinal loss of albumin consistent with protein-losing enteropathy.

(0.09MB).

PLE encompasses a diverse group of disorders associated with excessive serum protein loss, by way of the digestive tract. Diagnosis is made through 99mTc-labeled human albumin scintigraphy or fecal/plasma clearance of alpha 1-antitrypsin. SLE is a rare cause of PLE. Vasculitis, lymphatic ectasia, and the increase in vascular permeability are the mechanisms that explain PLE in SLE. Treatment with steroids and immunosuppressants reverses PLE in a high percentage of cases.

Ethical considerations

The authors declare that the procedures followed conformed with the ethical standards of the responsible committee on human experimentation, in accordance with the World Medical Association Declaration of Helsinki, and with the patient's informed consent. They also declare that the patient data was handled confidentially and anonymously.

Please cite this article as: González-Regueiro JA, Rico-Rodríguez OC, Valdovinos-Díaz MA. Enteropatía perdedora de proteínas: una manifestación inicial poco habitual de lupus eritematoso sistémico. Revista de Gastroenterología de México. 2019;84:511–512.s

Copyright © 2019. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México

Subscribe to our newsletter

Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.